RE:RE:RE:RE:RE:RE:RE:RE:RE:New Press Release - Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling StudyAnother giant step towards pelareorep's potential Accelerated Approval. In 2022, approximately 604,900 women were diagnosed with breast cancer in the WHO Europe region. Incidence in the EU-27 in 2022 was estimated to be 375,000
Therefore approximately 243,000 mBC patients would be diagnosed with HR+/HER2- in the EU-27, for example. Of this conservative number, approximately 67,000 would be further modeled for pelareorep + paclitaxel therapy in addition to the 55,000 HR+/HER2- mBC patients modeled in the United States.
Consequently around 122,000 pelareorep eligible HR+/HER2- mBC patients is the cumulative number that could be more appropriately modeled for the pelareorep in mBC target in the combined United States and EU-27 global regions. Using ONCY's conservative modeling equations, peak pelareorep annual sales would reach approximately US$5.8 Billion in HR+/HER2- mBC alone.